Page 39 - 18F-FDG PET as biomarker in aggressive lymphoma; technical and clinical validation

Interim PET as biomarker of response in HL and DLBCL?
References
1. Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25(5):579-586.
2. Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and NonHodgkin Lymphoma: The Lugano Classification. J Clin Oncol. 2014;32(27):3059-3068.
3. Barrington SF, Mikhaeel NG, Kostakoglu L, et al. Role of imaging in the staging and response assessment of lymphoma: consensus of the international conference on malignant lymphomas imaging working group. J Clin Oncol. 2014;32(27):3048-3058.
4. Barrington SF, Kirkwood AA, Franceschetto A, et al. PET-CT for staging & early response: results from ‘Response Adapted Therapy in Advanced Hodgkin Lymphoma’ (RATHL) (CRUK/07/033). Blood. 2016;127(12):1531-1538.
5. Biggi A, Gallamini A, Chauvi S, et al. International validation study for interim PET in ABVD- treated, advanced-stage Hodgkin lymphoma: interpretation criteria and concordance rate among reviewers. J Nucl Med. 2013;54(5):683-690.
6. Itti E, Meignan M, Berriolo-Riedinger A, et al. An international confirmatory study of the prognostic value of early PET/CT in diffuse large B-cell lymphoma: comparison between Deauville criteria and ∆SUVmax. Eur J Nucl Med Mol Imaging. 2013;40(9):1312-1320.
7. Boellaard R, Delgado-Bolton R, Oyen WJG, et al. FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging. 2015;42(2):328-354.
8. Radford J, Illidge T, Counsell N, et al. Results of a trial of PET-directed therapy for early-stage Hodgkin’s lymphoma. N Engl J Med. 2015;372(17):1598-1607.
9. Raemaekers JM, André MP, Federico M, et al. Omitting radiotherapy in early positron emission tomography-negative stage I/II Hodgkin lymphoma is associated with an increased risk of early relapse: Clinical results of the preplanned interim analysis of the randomized EORTC/LYSA/FIL H10 trial. J Clin Oncol. 2014;32(12):1188-1194.
10. Meyer RM, Gospodarowicz MK, Connors JM, et al. ABVD alone versus radiation-based therapy in limited-stage Hodgkin’s lymphoma. N Engl J Med. 2012;366(5):399-408.
11. Press OW, Li H, Schöder H, et al. US Intergroup Trial of Response-Adapted Therapy for Stage III to IV Hodgkin Lymphoma Using Early Interim Fluorodeoxyglucose-Positron Emission Tomography Imaging: Southwest Oncology Group S0816. J Clin Oncol. 2016;34(17):2020-2027.
12. Johnson PW, Federico M, Kirkwood A, Fossa A, et al. Adapted treatment guided by interim PET-CT scan in advanced Hodgkin’s lymphoma. N Engl J Med. 2016;374(25):2419-2429.
13. Terasawa T, Lau J, Bardet S, et al. Fluorine-18-fluorodeoxyglucose positron emission tomography for interim response assessment of advanced-stage Hodgkin’s lymphoma and diffuse large B-cell lymphoma: a systematic review. J Clin Oncol. 2009;27(11):1906-1914.
14. Moskowitz CH,Schöder H,Teruya-Feldstein J,et al.Risk-adapted Dose-Dense Immunochemotherapy Determined by Interim FDG-PET in Advanced-Stage Diffuse Large B-Cell Lymphoma. J Clin Oncol. 2010;28(11):1896-1903.
15. Juweid ME, Stroobants S, Hoekstra OS, et al. Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol. 2007;25(5):571-578.
16. Casasnovas RO, Meignan M, Berriolo-Riedinger A, et al. SUVmax reduction improves early prognosis value of interim positron emission tomography scan in diffuse large B-cell lymphoma. Blood. 2011;118(1):37-43.
17. Mikhaeel NG, Smith D, Dunn JT, et al. Combination of baseline metabolic tumour volume and early response on PET/CT improves progression-free survival prediction in DLBCL. Eur J Nucl Med Mol Imaging. 2016;43(7):1209-1219.
18. Zijlstra JM, Hoekstra OS, de Vet HCW. Validation of interim PET as a biomarker of response in NHL- a study on PET timing, therapies, response criteria, type of NHL and cost-effectiveness. Menton 2014. Available from: http://www.lymphomapet.com/files/Poster% 20Session%202014.pdf.
37
2